[go: up one dir, main page]

ATE391777T1 - Verwendung von prohibitin-rns in krebsbehandlung - Google Patents

Verwendung von prohibitin-rns in krebsbehandlung

Info

Publication number
ATE391777T1
ATE391777T1 AT99935916T AT99935916T ATE391777T1 AT E391777 T1 ATE391777 T1 AT E391777T1 AT 99935916 T AT99935916 T AT 99935916T AT 99935916 T AT99935916 T AT 99935916T AT E391777 T1 ATE391777 T1 AT E391777T1
Authority
AT
Austria
Prior art keywords
prohibitin
rna
utr
portions
tumors
Prior art date
Application number
AT99935916T
Other languages
English (en)
Inventor
Eldon Jupe
Original Assignee
Oklahoma Med Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oklahoma Med Res Found filed Critical Oklahoma Med Res Found
Application granted granted Critical
Publication of ATE391777T1 publication Critical patent/ATE391777T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Plant Pathology (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AT99935916T 1998-07-24 1999-07-24 Verwendung von prohibitin-rns in krebsbehandlung ATE391777T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US9397798P 1998-07-24 1998-07-24

Publications (1)

Publication Number Publication Date
ATE391777T1 true ATE391777T1 (de) 2008-04-15

Family

ID=22242037

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99935916T ATE391777T1 (de) 1998-07-24 1999-07-24 Verwendung von prohibitin-rns in krebsbehandlung

Country Status (6)

Country Link
EP (1) EP1100892B1 (de)
JP (1) JP2002522014A (de)
AT (1) ATE391777T1 (de)
CA (1) CA2336595A1 (de)
DE (1) DE69938501D1 (de)
WO (1) WO2000005359A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004026111A2 (en) 2000-11-16 2004-04-01 Microspherix Llc Flexible and/or elastic brachytherapy seed or strand
EP1791957B1 (de) 2004-09-23 2013-07-31 AEterna Zentaris GmbH Prohibitin als ziel für krebstherapie
US20090258020A1 (en) * 2008-01-07 2009-10-15 Patrys Limited Antibody designated barb3, barb3 related antibodies, and methods of making and using same
WO2021058145A1 (en) * 2019-09-24 2021-04-01 Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft Phage t7 promoters for boosting in vitro transcription

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5658792A (en) * 1990-11-14 1997-08-19 The United States Of America As Represented By The Department Of Health And Human Services Antiproliferative protein
US5922852A (en) * 1995-06-07 1999-07-13 Oklahoma Medical Research Foundation 3' untranslated region of the human prohibitin gene
EP0943017B1 (de) * 1996-11-07 2001-01-31 Oklahoma Medical Research Foundation Test zur diagnose eines erhöhten brustkrebs-risikos

Also Published As

Publication number Publication date
EP1100892B1 (de) 2008-04-09
WO2000005359A1 (en) 2000-02-03
EP1100892A1 (de) 2001-05-23
CA2336595A1 (en) 2000-02-03
DE69938501D1 (de) 2008-05-21
JP2002522014A (ja) 2002-07-23

Similar Documents

Publication Publication Date Title
NO20014058L (no) TRPM-2-antisense-terapi
MXPA01010393A (es) Tratamiento de neoplasmas con virus.
ATE334657T1 (de) Hemmung der bcl-2 protein expression durch liposomale antisense-oligodeoxynukleotide
EP1165594A4 (de) Antisens oligonucleotide-modulierung der stat3 expression
AU2001290706A1 (en) Antisense modulation of clusterin expression
WO2005030121A3 (en) Compounds, compositions and methods
DK0928335T3 (da) Fremgangsmåde til anvendelse af oligonukleotider med modificerede CpG-dinukleosider
ATE221914T1 (de) Gegenläufige oligonukleotide mit hemmender wirkung auf tumorbildung
MX9804009A (es) Inhibicion de crecimiento tumoral por oligonucleotidos de antisentido para il-8 y receptor de il-8.
WO2002036743A3 (en) Antisense modulation of calreticulin expression
ATE312202T1 (de) Menschliche rnase h und entsprechende oligonukleotidverbindungen
EP1242060A4 (de) Behandlung von krankheiten mit metastasenbildung
BR0008788A (pt) Sequencias anti-sentido antitumor dirigidas contra componentes r1 e r2 de ribonucleotìdeo reductase
WO2001032832A3 (en) Antisense inhibition of nucleolin expression
JP2006503904A5 (de)
EP1123414A4 (de) Antisense modulation der expression von integrin alpha 4
EP1513859A4 (de) Kinasesuppressor der ras-inaktivierung zur therapie von durch ras vermittelter tumorgenese
ATE307886T1 (de) Nukleotidsequenzen, proteine, medikamente und diagnoseagentien zur anwendung in krebsbehandlung
HUP0104046A2 (hu) Adenovírus-közvetített génterápia
ATE406155T1 (de) Triptolid-prodrugs zur krebstherapie
EP1004319A4 (de) Medikamente für massive tumore, welche inhibitoren der expression des wilms' tumorgens enthalten
EP1190040A4 (de) Herpes-simplex virus, das fremde gene exprimiert, und ein verfahren, um damit krebs zu behandeln
IL121272A0 (en) Nucleotide comprising compositions and their use for improving therapeutic index of a therapeutic drug
DE69938501D1 (de) Verwendung von prohibitin-rns in krebsbehandlung
WO2003104397A3 (en) ANTISENSE MODULATION OF PROTEIN KINASE GR 6 EXPRESSION

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties